Current therapeutic approaches for patients with myelodysplastic syndromes

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 131-143

  Greenberg, Peter L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

classification; iron chelation; myelodysplastic syndromes; prognosis; treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; AZACITIDINE; CLOFARABINE; CYCLOSPORIN; CYTARABINE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ELTROMBOPAG; ERYTHROPOIETIN; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ROMIPLOSTIM; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CLINICAL FEATURE; DRUG COST; ERYTHROCYTE TRANSFUSION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; LIVER TOXICITY; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK MANAGEMENT; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; IRON CHELATING AGENTS; MUTATION; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE;

EID: 77954323523     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08226.x     Document Type: Review

References (106)

1. Adès, L., Boehrer, S., Prebet, T., Beyne-Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M.P., Delaunay, J., Laurent, G., Vey, N., Burcheri, S., Mbida, R.M., Hoarau, N., Gardin, C. Fenaux, P. (2009) Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion, results of a phase 2 study. Blood, 113, 3947 3952.
2. Albitar, M., Johnson, M., Do, K.A., Day, A., Jilani, I., Pierce, S., Estey, E., Kantarjian, H., Keating, M., Verstovsek, S., O'brien, S. Giles, F.J. (2007) Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome, association with clinical behavior and outcome of induction therapy. Leukemia, 21, 480 488.
3. Alessandrino, E.P., Amadori, S., Barosi, G., Cazzola, M., Grossi, A., Liberato, L.N., Locatelli, F., Marchetti, M., Morra, E., Rebulla, P., Visani, G. Tura, S. (2002) Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 87, 1286 1306.
4. Alessandrino, E.P., Della Porta, M., Bacigalupo, A., Van Lint, M.T., Falda, M., Onida, F., Bernardi, M., Iori, A.P., Rambaldi, A., Cerretti, R., Marenco, P., Pioltelli, P., Malcovati, L., Pascutto, C., Oneto, R., Fanin, R. Bosi, A. (2008) WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome, a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood, 112, 895 902.
5. Alessandrino, E.P., Della Porta, M., Bacigalupo, A., Malcovati, L., Angelucci, E., Van Lint, M.T., Falda, M., Onida, F., Bernardi, M., Guidi, S., Lucarelli, B., Rambaldi, A., Cerretti, R., Marenco, P., Pioltelli, P., Pascutto, C., Oneto, R., Pirolini, L., Fanin, R. Bosi, A. (2009) Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation, a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica, 95, 476 484.
6. Alyea, E.P., Kim, H., Ho, V., Cutler, C., Gribben, J., DeAngelo, D.J., Lee, S.J., Windawi, S., Ritz, J., Stone, R.M., Antin, J.H. Soiffer, R.J. (2005) Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood, 105, 1810 1814.
7. Angelucci, E., Brittenham, G., McLaren, C.E., Ripalti, M., Baronciani, D., Giardini, C., Galimberti, M., Polchi, P. Lucarelli, G. (2000) Hepatic iron concentration and total body iron stores in thalassemia major. New England Journal of Medicine, 343, 327 331.
8. Apperley, J.F., Gardembas, M., Melo, J.V., Russell-Jones, R., Bain, B.J., Baxter, E.J., Chase, A., Chessells, J.M., Colombat, M., Dearden, C.E., Dimitrijevic, S., Mahon, F.X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N.C. Goldman, J.M. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet derived growth factor receptor beta. New England Journal of Medicine, 347, 481 487.
9. Arber, D., Porwit, A., Brunning, R.D., Orazi, A., Le Beau, M.M., Bain, B.J., Vardiman, J.W. Greenberg, P.L. (2008) Acute myeloid leukemia with myelodysplasia related changes in Chapter 6, acute myeloid leukemia and related precursor neoplasms. In : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Lyon, France, 4th edn (ed. by S. Swerdlow, E. Campo, N.L. Harris, E. Jaffe, S. Pilerie, H. Stein, J. Thiele J.W. Vardiman pp. 124 126. IARC Press
10. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., Harris, M.A., Hill, D.P., Issel-Tarver, L., Kasarskis, A., Lewis, S., Matese, J.C., Richardson, J.E., Ringwald, M., Rubin, G.M. Sherlock, G. (2000) Gene Ontology: tool for the unification of biology. Nature Genetics, 25, 25 29.
11. Baxter, E.J., Kulkarni, S., Vizmanos, J.L., Jaju, R., Martinelli, G., Testoni, N., Hughes, G., Salamanchuk, Z., Calasanz, M.J., Lahortiga, I., Pocock, C.F., Dang, R., Fidler, C., Wainscoat, J.S., Boultwood, J. Cross, N.C. (2003) Novel translocations that disrupt the platelet derived growth factor receptor beta (PDGFRB) gene in BCR ABL negative chronic myeloproliferative disorders. British Journal of Haematology, 120, 251 256.
12. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189 199.
13. Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D. Parker, J. (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology, 120, 187 200.
14. Brunning, R., Orazi, A., Germing, U., LeBeau, M., Porwit, A., Baumann, I., Vardiman, J. Hellstrom-Lindberg, E. (2008) Myelodysplastic Syndromes in Chapter 5. In : World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed. by S.H. Swerdlow, E. Campo, N.L. Harris et al pp. 88 103. IARC Press
15. Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarré, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. Fenaux, P. (2004) Health, economic, and quality of life effects of erythropoietin and granulocyte colony stimulating factor for the treatment of myelodysplastic syndromes, a randomized, controlled trial. Blood, 104, 321 327.
16. Cazzola, M. (2009) Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica, 94, 1041.
17. Cazzola, M. Malcovati, L. (2009). Risk-Adapted Treatment of Myelodysplastic Syndromes, Vol. 3, pp. 181 187. Education Book, European Hematology Association meeting
18. Cheson, B.D., Greenberg, P., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S., Schiffer, C.A. Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419 425.
19. Cools, J., Stover, E., Wlodarska, I., Marynen, P. Gilliland, D.G. (2004) The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Current Opinion in Hematology, 11, 51 57.
20. Cutler, C.S., Lee, S., Greenberg, P., Deeg, H.J., Pérez, W.S., Anasetti, C., Bolwell, B.J., Cairo, M.S., Gale, R.P., Klein, J.P., Lazarus, H.M., Liesveld, J.L., McCarthy, P.L., Milone, G.A., Rizzo, J.D., Schultz, K.R., Trigg, M.E., Keating, A., Weisdorf, D.J., Antin, J.H. Horowitz, M.M. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes, delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood, 104, 579 585.
21. Czibere, A., Burns, I., Junge, B., Singh, R., Kobbe, G., Haas, R. Germing, U. (2009) Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival. Haematologica, 94, 1453 1455.
22. Davis, R.E. Greenberg, P. (1998) Bcl-2 expression by myeloid precursors in myelodysplastic syndromes, Impact on disease progression. Leukemia Research, 22, 767 777.
23. Della Porta, M.G., Malcovati, L., Boveri, E., Travaglino, E., Pietra, D., Pascutto, C., Passamonti, F., Invernizzi, R., Castello, A., Magrini, U., Lazzarino, M. Cazzola, M. (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. Journal of Clinical Oncology, 27, 754 762.
24. Di Tucci, A.A., Matta, G., Deplano, S., Gabbas, A., Depau, C., Derudas, D., Caocci, G., Agus, A. Angelucci, E. (2008) Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemia. Haematologica, 93, 1385 1388.
25. Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. Cabantchik, Z.I. (2003) Labile plasma iron in iron overload, redox activity and susceptibility to chelation. Blood, 102, 2670 2677.
26. Estey, E. (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. Journal Clinical of Oncology, 25, 1908 1915. (Pubitemid 46854425)
27. Estey, E.H., Thall, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M. Beran, M. (2001) Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 3575 3583.
28. Faderl, S., Ravandi, F., Huang, X., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Borthakur, G., Verstovsek, S., Thomas, D.A., Kwari, M. Kantarjian, H.M. (2008) A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 112, 1638 1645.
29. Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muu, P., Boekhorst, P., Sanz, G., Cañizo, C., Guerci-Bresler, A., Schlegelberger, A., Aul, C., Kreipe, H., Goehring, G., Knight, R., Francis, J., Fu, T. Hellstrom-Lindberg, E. (2009a) RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Patients with Low- or Int-1-Risk MDS with Del(5q): Results From a Randomized Phase III Trial (MDS-004). Blood (ASH Meeting Abstracts), 114, 390a. Abstract #944.
30. Fenaux, P., Mufti, G., Hellstrom Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., Gore, S.D., Seymour, J.F., Bennett, J.M., Byrd, J., Backstrom, J., Zimmerman, L., McKenzie, D., Beach, C. Silverman, L.R. (2009b) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes, a randomised, open label, phase III study. Lancet Oncology, 10, 223 232.
31. Gleixner, K.V., Mayerhofer, M., Aichberger, K.J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P.W., Fabbro, D., Pickl, W.F., Sillaber, C. Valent, P. (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT, comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 107, 752 759.
32. Göhring, G., Giagounidis, A., Büsche, G., Kreipe, H.H., Zimmermann, M., Hellström-Lindberg, E., Aul, C. Schlegelberger, B. (2009) Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Annals of Hematology, 89, 365 374.
33. Goss, T.F., Szende, A., Schaefer, C., Totten, P.J., Knight, R., Jädersten, M., Hellström-Lindberg, E. List, A.F. (2006) Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control, 13, 17 25.
34. Gotlib, J., Berubé, C., Growney, J.D., Chen, C.C., George, T.I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S.L., Durocher, J.A., Lichy, J.H., Wang, Y., Cohen, P.S., Arber, D.A., Heinrich, M.C., Neckers, L., Galli, S.J., Gilliland, D.G. Coutré, S.E. (2005) Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood, 106, 2865 2870.
35. Gotlib, J., Lavori, P., Quesada, S., Stein, R., Shahnia, S. Greenberg, P.L. (2008) A PHASE II intra-patient dose-escalation trial of darbepoetin alfa with or without granulocyte colony-stimulating factor in myelodysplastic syndromes. American Journal of Hematology, 84, 15 20.
36. Greenberg, P.L. (2006a) Clinical and prognostic characterization of myelodysplastic syndromes. In : Myelodysplastic Syndromes: Clinical and Biological Advances (ed. by P.L. Greenberg pp. 1 32. Cambridge University Press
37. Greenberg, P.L. (2006b) Pathogenetic mechanisms underlying myelodysplastic syndromes. myelodysplastic syndromes. In : Myelodysplastic Syndromes: Clinical and Biological Advances (ed. by P.L. Greenberg pp. 63 94. Cambridge University Press
38. Greenberg, P., Taylor, K., Larson, R., Koeffler, P., Negrin, R., Saba, H., Ganser, A., Jakubowski, A., Gabrilove, J., Mufti, G., Cruz, J., Hammond, W., Broudy, V., Langley, G.R., Keating, A., LeBeau, M., Vardiman, J., Lamborn, K. Brown, S. (1993) Phase III randomized multicenter trial of recombinant human G-CSF in MDS. Blood, 82 (Suppl 1 196a.
39. Greenberg, P., Cox, C., Le Beau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079 2088.
40. Greenberg, P.L., Bishop, M., Deeg, J., Erba, H., Gore, S., Nimer, S., O'Donnell, M., Tallman, M., Bennett, J., Estey, E. Stone, R. (1998) NCCN practice guidelines for myelodysplastic syndromes. Oncology, 12, 53 80.
41. Greenberg, P.L., Cosler, L.E., Ferro, S.A. Lyman, G.H. (2008) The costs of drugs used to treat Myelodyplastic Syndromes following National Comprehensive Cancer Network guidelines. Journal of the National Comprehensive Cancer Network, 6, 942 953.
42. Greenberg, P.L., Attar, E., Battiwalla, M., Bennett, J.M., Bloomfield, C., Deeg, H.J., Erba, H., Foran, J., Gore, S., Maness, L., Millenson, M., Nimer, S., O'Donnell, M., Saba, H., Spiers, K., Stone, R. Tallman, M. (2009a) NCCN practice guidelines for myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network, 6, 902 925.
43. Greenberg, P.L., Sun, Z., Miller, K.B., Bennett, J.M., Tallman, M.S., Dewald, G., Paietta, E., Van der Jagt, R., Houston, J., Thomas, M.L., Cella, D. Rowe, J.M. (2009b) Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor, results of a prospective randomized phase iii trial by the Eastern Cooperative Oncology Group (E1996). Blood, 114, 2393 2400.
44. Greenberg, P.L., Garcia-Manero, G., Moore, M.R., Damon, L.E., Roboz, G.J., Wei, H., Kantarjian, H. Franklin, J.L. (2009c) Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine. Blood, 114, 703a.
45. Greenberg, P.L., Rigsby, C., Stone, R.M., Deeg, J., Gore, S., Millenson, M., Nimer, S., O'Donnell, M., Shami, P. Kumar, R. (2009d) NCCN Task Force Report, transfusion and iron overload in patients with myelodysplastic syndromes. Journal of the National Comprehensive Cancer Network, 7, S1 S16.
46. Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A.A., Aul, C., Trümper, L., Krieger, O., Stauder, R., Müller, T.H., Wimazal, F., Valent, P., Fonatsch, C. Steidl, C. (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes, evidence from a core dataset of 2124 patients. Blood, 110, 4385 4395.
47. Hellstrom-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes, a meta analysis of 205 patients from 17 studies. British Journal of Haematology, 89, 67 71.
48. Hellstrom-Lindberg, E., Negrin, R., Stein, R., Krantz, S., Lindberg, G., Vardiman, J., Ost, A. Greenberg, P. (1997) Erythroid response to treatment with G CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes, proposal for a predictive model. British Journal of Haematology, 99, 344 351.
49. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Löfvenberg, E., Oberg, G., Porwit-MacDonald, A., Rådlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony stimulating factor, significant effects on quality of life. British Journal of Haematology, 120, 1037 1046.
50. Jadersten, M., Malcovati, L., Dybedal, I., Della Porta, M.G., Invernizzi, R., Montgomery, S.M., Pascutto, C., Porwit, A., Cazzola, M. Hellström-Lindberg, E. (2008) Erythropoietin and granulocyte colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. Journal of Clinical Oncology, 26, 3607 3613.
51. Jaeger, M., Aul, C., Sohngen, D., Germing, U. Schneider, W. (1992) Iron overload in polytransfused patients with MDS, the use of L1 for oral iron chelation. Drugs of Today, 28, 143 147.
52. Kantarjian, H, Giles, F, List, A, Lyons, R, Sekeres, MA, Pierce, S, Deuson, R Leveque, J. (2007a) The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer, 109, 1705 1714. (Pubitemid 46668530)
53. Kantarjian, H.M., O'Brien, S., Shan, J., Aribi, A., Garcia-Manero, G., Jabbour, E., Ravandi, F., Cortes, J., Davisson, J. Issa, J.P. (2007b) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer, 109, 265 273.
54. Kantarjian, H., O'Brien, S., Cortes, J., Wierda, W., Faderl, S., Garcia-Manero, G., Issa, J.P., Estey, E., Keating, M. Freireich, E.J. (2008) Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer, 113, 1933 1952.
55. Kantarjian, H., Fenaux, P., Sekeres, M.A., Becker, P.S., Boruchov, A., Bowen, D., Hellstrom-Lindberg, E., Larson, R.A., Lyons, R.M., Muus, P., Shammo, J., Siegel, R., Hu, K., Franklin, J. Berger, D.P. (2009) Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology, 24, 7999.
56. Kao, J.M. Greenberg, P.L. (2007) Myelodysplastic Syndromes: impact of recently analyzed variables for modifying current classification methods. Clinical Leukemia, 1, 172 182.
57. Kao, J.M., McMillan, A. Greenberg, P.L. (2008) International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed, impact of cytopenias on clinical outcomes in myelodysplastic syndromes. American Journal of Hematology, 83, 765 770.
58. Kornblith, A.B., Herndon, J., Silverman, L.R., Demakos, E.P., Odchimar-Reissig, R., Holland, J.F., Powell, B.L., DeCastro, C., Ellerton, J., Larson, R.A., Schiffer, C.A. Holland, J.C. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial, a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 20, 2441. 452.
59. Kosmider, O., Gelsi-Boyer, V., Cheok, M., Grabar, S., Della-Valle, V., Picard, F., Viguié, F., Quesnel, B., Beyne-Rauzy, O., Solary, E., Vey, N., Hunault-Berger, M., Fenaux, P., Mansat-De Mas, V., Delabesse, E., Guardiola, P., Lacombe, C., Vainchenker, W., Preudhomme, C., Dreyfus, F., Bernard, O.A., Birnbaum, D. Fontenay, M. (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes. Blood, 114, 3285 3291.
60. Laport, G.G., Sandmaier, B., Storer, B.E., Scott, B.L., Stuart, M.J., Lange, T., Maris, M.B., Agura, E.D., Chauncey, T.R., Wong, R.M., Forman, S.J., Petersen, F.B., Wade, J.C., Epner, E., Bruno, B., Bethge, W.A., Curtin, P.T., Maloney, D.G., Blume, K.G. Storb, R.F. (2008) Reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biology of Blood and Marrow Transplantion, 14, 246 255.
61. Le Lan, C., Loréal, O., Cohen, T., Ropert, M., Glickstein, H., Lainé, F., Pouchard, M., Deugnier, Y., Le Treut, A., Breuer, W., Cabantchik, Z.I. Brissot, P. (2005) Association between hepatic damage, iron overload and incidence of redox-active iron in the plasma. Blood, 105, 4527 4531.
62. Lim, Z.Y., Killick, S., Germing, U., Cavenagh, J., Culligan, D., Bacigalupo, A., Marsh, J. Mufti, G.J. (2007) Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia, 21, 1436 1441.
63. Lim, K.H., Tefferi, A., Lasho, T., Finke, C., Patnaik, M., Butterfield, J., McClure, R., Li, C.L. Pardanani, A. (2009) Systemic mastocytosis in 342 consecutive adults, survival studies and prognostic factors. Blood, 113, 5727 5736.
64. de Lima, M., Anagnostopoulos, A., Munsell, M., Shahjahan, M., Ueno, N., Ippoliti, C., Andersson, B.S., Gajewski, J., Couriel, D., Cortes, J., Donato, M., Neumann, J., Champlin, R. Giralt, S. (2004) Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood, 104, 865 872.
65. List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J. Knight, R. (2006) Hematologic and cytogenetic response to lenalidomide in myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine, 355, 1456 1465.
66. Lyman, G.H., Berndt, E., Kallich, J.D., Erder, M.H., Crown, W.H., Long, S.R., Lee, H., Song, X. Finkelstein, S.N. (2005) The economic burden of anemia in cancer patients receiving chemotherapy. Value in Health, 8, 149 156.
67. Magnusson, M.K., Meade, K., Nakamura, R., Barrett, J. Dunbar, C.E. (2002) Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood, 100, 1088 1091.
68. Malcovati, L., Porta, M., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. Cazzola, M. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making. Journal of Clinical Oncology, 23, 7594 7603.
69. Mannone, L., Gardin, C., Quarre, M.C., Bernard, J.F., Vassilieff, D., Ades, L., Park, S., Vaultier, S., Hamza, F., Beyne-rauzy, M.O., Cheze, S., Giraudier, S., Agape, P., Legros, L., Voillat, L., Dreyfus, F. Fenaux, P. (2006) High dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. British Journal of Haematology, 133, 513 519.
70. McClune, B.L. Weisdorf, D.J. (2010) Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care? Current Opinion in Hematology, 17, 133 138.
71. Mills, K., Kohlmann, A., Williams, P.M., Wieczorek, L., Liu, W.M., Li, R., Wei, W., Bowen, D.T., Loeffler, H., Hernandez, J.M., Hofmann, W.K. Haferlach, T. (2009) Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. Blood, 114, 1063 1072.
72. Mundle, S., Lefebvre, P., Vekeman, F., Duh, M.S., Rastogi, R. Moyo, V. (2009) An assessment of erythroid response to epoetin-a as a single agent versus in combination with granulocyte- or granulocyte- macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer, 115, 706 715.
73. Musto, P., Lanza, F., Balleari, E., Grossi, A., Falcone, A., Sanpaolo, G., Bodenizza, C., Scalzulli, P.R., La Sala, A., Campioni, D., Ghio, R., Cascavilla, N. Carella, A.M. (2005) Darbepoetin alpha for the treatment of anaemia in low intermediate risk myelodysplastic syndromes. British Journal of Haematology, 128, 204 209.
74. Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. Greenberg, P.L. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony stimulating factor and erythropoietin, evidence for in vivo synergy. Blood, 87, 4076 4081.
75. Nordic MDS Group (2010) Guidelines for the diagnosis and treatment of Myelodysplastic Syndromes, Issue 5, 4th update. Available at : http://www.nordicmds.org/ez4/index.php?/nmds/Nordic-Care-Programme.
76. Olivieri, N.F. Brittenham, G. (1997) Iron chelating therapy and the treatment of thalassemia. Blood, 89, 739 761.
77. Olivieri, N.F., Nathan, D., MacMillan, J.H., Wayne, A.S., Liu, P.P., McGee, A., Martin, M., Koren, G. Cohen, A.R. (1994) Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine, 331, 574 578.
78. Olsen, R.J., Dunphy, C., O'Malley, D.P., Rice, L., Ewton, A.A. Chang, C.C. (2008) The implication of identifying JAK2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis. Journal of Hematopathology, 1, 111 117.
79. Pagel, J.M., Gooley, T., Rajendran, J., Fisher, D.R., Wilson, W.A., Sandmaier, B.M., Matthews, D.C., Deeg, H.J., Gopal, A.K., Martin, P.J., Storb, R.F., Press, O.W. Appelbaum, F.R. (2009) Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 114, 5444 5453.
80. Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.T., Cheze, S., Mahé, B., Ferrant, A., Ravoet, C., Escoffre-Barbe, M., Adès, L., Vey, N., Aljassem, L., Stamatoullas, A., Mannone, L., Dombret, H., Bourgeois, K., Greenberg, P., Fenaux, P. Dreyfus, F. (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G CSF, the GFM experience. Blood, 111, 574 582.
81. Parker, J.E., Mufti, G., Rasool, F., Mijovic, A., Devereux, S. Pagliuca, A. (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood, 96, 3932 3938.
82. Piga, A., Galanello, R., Forni, G.L., Cappellini, M.D., Origa, R., Zappu, A., Donato, G., Bordone, E., Lavagetto, A., Zanaboni, L., Sechaud, R., Hewson, N., Ford, J.M., Opitz, H. Alberti, D. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 91, 873 880.
83. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., Hershko, C. Cappellini, M.D. (2009) High non-transferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 84, 29 33.
84. Platzbecker, U., Bornhauser, M., Germing, U., Stumpf, J., Scott, B.L., Kröger, N., Schwerdtfeger, R., Böhm, A., Kobbe, G., Theuser, C., Rabitsch, W., Valent, P., Sorror, M.L., Ehninger, G. Deeg, H.J. (2008) Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biology of Blood and Marrow Transplantion, 14, 1217 1225.
85. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D. Rose, C. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670), a 1-yr prospective study. 2008. European Journal of Haematology, 80, 168 176.
86. Rawlins, M. (2008) NICE, National implementation programme, National Institute for Health and Clinical Excellence
87. Rawlins, M. (2009) The NICE way of influencing health spending: a conversation with Sir Michael Rawlins. Interview by Nicholas Timmins. Health Affairs (Millwood), 28, 1360 1365.
88. Raza, A., Reeves, J., Feldman, E.J., Dewald, H.J., Dreisbach, G.W., Bennett, J.M., Deeg, R.M., Greenberg, L., Schiffer, C.A., Stone, V.M., Shammo, P.L., Curtin, P.T., Klimek, R.D., Schmidt, J.M., Thomas, D., Knight, M., Wride, K., Zeldis, J.B. List, A.F. (2008) Phase 2 study of lenalidomide in transfusion dependent, low risk, and intermediate 1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood, 111, 86 93.
89. Saunthararajah, Y., Nakamura, R., Nam, J.M., Robyn, J., Loberiza, F., Maciejewski, J.P., Simonis, T., Molldrem, J., Young, N.S. Barrett, A.J. (2002) HLA DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 100, 1570 1574.
90. Silverman, L.R. (2009) Hypomethylating agents in myelodysplastic syndromes changing the inevitable, the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leukemia Research, 33, S18 S21.
91. Silverman, L.R., Demakos, E., Peterson, B.L., Kornblith, A.B., Holland, J., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. Holland, J. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome, a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429 2440. (Pubitemid 34525728)
92. Sloand, E.M., Wu, C.O., Greenberg, P., Young, N. Barrett, J. (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. Journal of Clinical Oncology, 26, 2505 2511.
93. Sloand, E., Olnes, M., Weinstein, B., Scheinberg, P. Young, N. (2009) Alemtuzumab treatment of Intermediate -1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. Blood, 114, p53a.
94. + Myelodysplastic Syndrome Marrow Cells to Disease Subtype and Progression. Blood, 114, 4847 4858.
95. St Pierre, T.G., Clark, P., Chua-anusorn, W., Fleming, A.J., Jeffrey, G.P., Olynyk, J.K., Pootrakul, P., Robins, E. Lindeman, R. (2005) Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood, 105, 855 861. (Pubitemid 40070775)
96. Stasi, R., Abruzzese, E., Lanzetta, G., Terzoli, E. Amadori, S. (2005) Darbepoetin alfa for the treatment of anemic patients with low and intermediate 1 risk myelodysplastic syndromes. Annals of Oncology, 16, 1921 1927.
97. Steensma, D.P., Baer, M., Slack, J.L., Buckstein, R., Godley, L.A., Garcia-Manero, G., Albitar, M., Larsen, J.S., Arora, S., Cullen, M.T. Kantarjian, H. (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes, the alternative dosing for outpatient treatment (ADOPT) trial. Journal of Clinical Oncology, 27, 3842 3848.
98. Steer, E.J. Cross, N. (2002) Myeloproliferative disorders with translocations of chromosome 5q31 35, role of the platelet derived growth factor receptor Beta. Acta Haematologica, 107, 113 122.
99. Szpurka, H., Tiu, R., Murugesan, G., Aboudola, S., Hsi, E.D., Theil, K.S., Sekeres, M.A. Maciejewski, J.P. (2006) Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood, 108, 2173 2181.
100. Tefferi, A., Verstovsek, S., Barosi, G., Passamonti, F., Roboz, G.J., Gisslinger, H., Paquette, R.L., Cervantes, F., Rivera, C.E., Deeg, H.J., Thiele, J., Kvasnicka, H.M., Vardiman, J.W., Zhang, Y., Bekele, B.N., Mesa, R.A., Gale, R.P. Kantarjian, H.M. (2009) Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Journal of Clinical Oncology, 27, 4563 4569.
101. Thomas, M. (2006) Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In : Myelodysplastic Syndromes: Clinical and Biological Advances (ed. by P.L. Greenberg pp. 263 295. Cambridge University Press
102. Valent, P., Horny, H., Bennett, J.M., Fonatsch, C., Germing, U., Greenberg, P.L., Haferlach, T., Haase, D., Kolb, H.J., Krieger, O., Loken, M., van de Loosdrecht, A., Ogata, K., Orfao, A., Pfeilstöcker, M., Rüter, B., Sperr, W.R., Stauder, R. Wells, D.A. (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes, Consensus statements and report from a working conference. Leukemia Research, 31, 727 736.
103. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellström-Lindberg, E., Tefferi,
104. Wallen, H., Gooley, T.A., Deeg, H.J., Pagel, J.M., Press, O.W., Appelbaum, F.R., Storb, R. Gopal, A.K. (2005) Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. Journal of Clinical Oncology, 23, 3439. 3446.
105. Yabroff, K.R., Wareen, J. Brown, M.L. (2007) Costs of cancer care in the USA, a descriptive review. Nature Clinical Practice Oncology, 4, 643 656.
106. Zipperer, E., Pelz, D., Nachtkamp, K., Kuendgen, A., Strupp, C., Gattermann, N., Haas, R. Germing, U. (2009) The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica, 94, 729 732.